在患有神经内分泌瘤的患者中,放射性体疗法诱导的葡萄糖代谢可能发生变化
Marek Saracyn1, Adam Daniel Durma2, Barbara Bober1
1Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Endokrynologia Polska
|March 17, 2025
概括
针对神经内分泌新生体的放射性治疗可能会略微增加禁食葡萄糖和胰岛素水平. 这种治疗仍然是安全的,没有在患者中观察到严重的葡萄糖相关副作用.
科学领域:
- 内分泌学 在内分泌学.
- 核医学就是核医学.
- 在瘤学瘤学.
背景情况:
- 神经内分泌新生体 (NENs) 是一组多样化的来自神经内分泌细胞的瘤,通常在胃肠道中发现.
- 放射性干疗法 (RLT) 是对渐进或不可操作的NENs的关键治疗方法.
- 在RLT期间调查代谢变化对于患者管理至关重要.
研究的目的:
- 评估在患有NENs的患者在放射性干治疗期间和之后葡萄糖代谢的变化.
- 评估RLT关于葡萄糖恒温的安全性和有效性.
主要方法:
- 一项涉及41名患有不可手术的神经内分泌瘤的患者进行RLT的研究.
- 治疗包括单独使用[177Lu]Lu-DOTA-TATE或与[177Lu]Lu-DOTA-TATE和[90Y]Y-DOTA-TATE一起进行合治疗.
- 在治疗期间和治疗后一年,分析了包括葡萄糖和胰岛素在内的实验室参数.
主要成果:
- 在RLT期间和之后,观察到空腹葡萄糖和胰岛素度的统计学上微不足道的增加.
- 接受双重治疗的患者表现出更高,但在统计学上无意义的禁食葡萄糖增加.
- 没有报告与葡萄糖代谢相关的严重不良事件 (CTCAE G3-G5).
结论:
- 放射性激素治疗可能会导致禁食葡萄糖水平的潜在增加,可能是由于周围葡萄糖代谢的变化.
- RLT是对NEN的安全治疗方法,不会引起严重的葡萄糖相关不良事件.
- 对于接受RLT的患者,建议持续监测葡萄糖代谢.
相关概念视频
Hypoglycemia and Glucagon
146
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
146
Radiological Investigation III: Pulmonary Angiogram and PET Scan
77
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
77
Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124
Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
Hormones Regulating Blood Glucose
3.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.0K
Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281


